eLife (Sep 2015)

FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase

  • Jikui Guan,
  • Ganesh Umapathy,
  • Yasuo Yamazaki,
  • Georg Wolfstetter,
  • Patricia Mendoza,
  • Kathrin Pfeifer,
  • Ateequrrahman Mohammed,
  • Fredrik Hugosson,
  • Hongbing Zhang,
  • Amy W Hsu,
  • Robert Halenbeck,
  • Bengt Hallberg,
  • Ruth H Palmer

DOI
https://doi.org/10.7554/eLife.09811
Journal volume & issue
Vol. 4

Abstract

Read online

Aberrant activation of anaplastic lymphoma kinase (ALK) has been described in a range of human cancers, including non-small cell lung cancer and neuroblastoma (Hallberg and Palmer, 2013). Vertebrate ALK has been considered to be an orphan receptor and the identity of the ALK ligand(s) is a critical issue. Here we show that FAM150A and FAM150B are potent ligands for human ALK that bind to the extracellular domain of ALK and in addition to activation of wild-type ALK are able to drive 'superactivation' of activated ALK mutants from neuroblastoma. In conclusion, our data show that ALK is robustly activated by the FAM150A/B ligands and provide an opportunity to develop ALK-targeted therapies in situations where ALK is overexpressed/activated or mutated in the context of the full length receptor.

Keywords